Vidant, GT Medical Technologies Announce First Patient Treated in Registry Trial of Gammatile Therapy for Brain Tumors | Beaufort County Now | The study will evaluate the safety and effectiveness of GammaTile Therapy in a real-world setting in up to 50 brain tumor centers across the United States.

Coronavirus Disease 2019 (COVID-19)

Vidant, GT Medical Technologies Announce First Patient Treated in Registry Trial of Gammatile Therapy for Brain Tumors

Press Release:

    Greenville, N.C.     Vidant Health and GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, announced the first patient has been enrolled into its registry trial of GammaTile®, a FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for newly diagnosed malignant and recurrent brain tumors. The study will evaluate the safety and effectiveness of GammaTile Therapy in a real-world setting in up to 50 brain tumor centers across the United States.

    "GammaTile Therapy was created with the goal of elevating the standard of care, and this registry will help demonstrate how it is making a measurable impact on patients diagnosed with brain tumors," said Matt Likens, President and CEO of GT Medical Technologies. "We have been encouraged by previous studies showing that GammaTile Therapy delays recurrence and may extend survival, which led to FDA clearance. This registry will shed further light on the real-world benefits of STaRT for people with brain tumors."

    The multicenter observational study will enroll 600 patients with brain tumors of any pathology who have received treatment with GammaTile Therapy. Data will be collected before and after surgery and implantation of GammaTiles and at 1, 3, 6, 9, 12, 18 and 24 months, then every 6 months through 5 years. Primary and secondary endpoints will include local tumor control, overall survival, quality of life, physical function, and safety. This will be the first observational registry study of resection plus GammaTile. Data from the study will be used to benchmark clinical outcomes for GammaTile Therapy and allow for comparisons to existing standard-of-care treatments for patients with brain tumors.

    Over 700,000 Americans are living with a brain tumor today. Despite the efforts of the most skilled brain tumor specialists in the world, outcomes for patients with brain tumors have improved little over the past 30 years. GammaTile is the latest FDA-cleared treatment for newly diagnosed malignant and recurrent brain tumors, and recently announced data show promising clinical outcomes for patients diagnosed with high grade gliomas, brain metastases, and aggressive meningiomas.

    "As a neurosurgeon, I am always looking for treatments that help give my patients more time and a better quality of life, and from what I have seen in my patients to date, GammaTile Therapy offers both," said Dr. Stuart Lee, Chief of Neurosurgery at Vidant Medical Center in Greenville, North Carolina. "It is an honor to have treated and enrolled the first patient in this registry. My hope is that the insights gleaned from this study will give us information to continue improving the standard of care for patients with brain tumors."

    In addition to the registry trial, two additional studies evaluating GammaTile Therapy in patients with brain metastases were announced at the 2020 Society of Neuro-Oncology Virtual Meeting on Brain Metastases in August. Those studies, which are led by The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center, are expected to begin enrollment in Q4 2020.


  • Contact: Brian Wudkwych
  •     brian.wudkwych@vidanthealth.com

Go Back

HbAD0

Latest Health and Fitness

The North Carolina Department of Health and Human Services today announced the state is expanding availability of its at-home COVID-19 test collection.
The North Carolina Department of Health and Human Services is launching an expanded COVID-19 screening testing program to support public, charter and private K-12 schools in protecting students and staff from the spread of COVID-19.
These decisions were made following an extensive interview process with members of the Vidant Health Board of Directors and leaders from across the organization.
As the Coronavirus pandemic, or COVID-19, progresses through mutation and spread throughout the world and, ultimately, the United States, BCN shall endeavor to keep the public informed.
The North Carolina Department of Health and Human Services today announced more than 80% of adults 65 and older in the state have received at least one dose of COVID-19 vaccine.
Vidant Health is proud to announce EastCare recently became one of the first medical flight programs in North Carolina to carry O Negative Whole Blood
The North Carolina Department of Health and Human Services today announced North Carolina has been approved by the U.S. Department of Agriculture to continue the Pandemic Electronic Benefits Transfer (P-EBT) food assistance program through Summer 2021.

HbAD1

Vidant Health is proud to announce a new collaboration with Mayo Clinic Laboratories that gives Vidant access to Mayo Clinic’s extensive menu of primary reference laboratory tests and clinical expertise
The North Carolina Department of Health and Human Services today announced the selection of organizations to serve three regions of the state
The North Carolina Department of Health and Human Services today announced all Medicaid beneficiaries currently eligible to transition to managed care have selected or been assigned a health plan with 97% enrolled in a plan that includes their current primary care provider (PCP) in network.
Vidant Health is aware scammers are calling community members in an attempt to solicit Medicare or financial information.
The North Carolina Department of Health and Human Services is launching a new public campaign encouraging North Carolinians to "Vax Up or Mask Up” to support the new guidance that lifts many of the state’s COVID-19 restrictions.
A new tool created by the NC Department of Health and Human Services that maps social vulnerability and vaccination rates by census tract has helped North Carolina vaccine providers increase vaccinations by 50 percent in 89 underserved communities.
As part of its ongoing effort to get more North Carolinians vaccinated and safely bring summer back, the North Carolina Department of Health and Human Services is offering $25 Summer Cash Cards at select vaccine sites to offset the time and transportation costs of getting vaccinated.
The North Carolina Department of Health and Human Services today expanded its NC COVID-19 Dashboard to include a new metric — wastewater monitoring.

HbAD2

 
Back to Top